Research use only. Not for human or animal consumption.La Jolla, CaliforniaLot lookupContact
MAROGENBIO

Compound guide

Tirzepatide (GP-2) reference standard

Tirzepatide's structure is fully documented, which makes its certificate checkable in a way retatrutide's is not. The two formats Marogen stocks, and why the GLP-2 pen name collides with a real hormone.

Catalog formats covered
2
Papers cited
2
Last reviewed
2026-11-12
Classification
Research use only
Buying this material?
Apply for wholesale pricing
01

What tirzepatide is

Published chemistry, not a measurement from any lot.

Tirzepatide, development code LY3298176, is a synthetic 39-residue lipidated peptide amide based on the human GIP sequence. The modifications are fully documented in the FDA substance registry and in the primary paper: alpha-aminoisobutyric acid at positions 2 and 13, a C20 fatty diacid attached at Lys20 through a gamma-glutamate and two ethylene-glycol linker units, and a C-terminal serinamide. The backbone reads YAEGTFTSDYSIGLDKIAQKAFVQWLIAGGPSSGAPPPS.

That level of public documentation is the practical difference between this material and retatrutide. Here the CAS number, formula and weight all agree across PubChem and the registry, so a certificate's figures can be checked against something authoritative rather than against other vendors. GP-2 remains a catalog label rather than a chemical name, and the pen name is a problem of its own: GLP-2 is a real, different 33-residue intestinal hormone, and tirzepatide is not it.

CAS
2023788-19-2
Molecular formula
C225H348N48O68
Molecular weight
4813.5 g/mol
Sequence
39-residue GIP/GLP-1 dual agonist, Aib2, Aib13, Lys20 C20 diacid via γGlu-2xOEG
Residues
39
Also searched as
tirz, GP-2

Compiled from public chemistry records (PubChem, FDA GSRS, UniProt). Values marked “awaiting confirmation” are not yet confirmed by Marogen. The certificate for a lot is the authority for every number on it. See the analytical reference table.

02

Formats Marogen stocks

Every tirzepatide listing in the catalog, with sizes and SKUs.

The lyophilized vial comes in six strengths from 5 mg to 60 mg, matching retatrutide for range, and it is the format for analytical work because a solid can be weighed and made up to a concentration the method sets rather than one the supplier filled.

The second format is a 20 mg prefilled research pen listed under the name GLP-2. Its concentration and fill volume are not published, because those are supplier product facts Marogen has not put on the site, and only total content appears. There is no tirzepatide nasal spray. If a method depends on knowing concentration, buy the vial or have the figure stated on the quote.

Catalog formats covered by this guide
ListingFormSizesSKUDocumentation
Tirzepatide (GP-2) Reference StandardLyophilized powder, sealed vial5 mg10 mg15 mg20 mg30 mg60 mgGP2-5MGGP2-10MGGP2-15MGGP2-20MGGP2-30MGGP2-60MGLot TIR10-1008 on file
GLP-2Prefilled research pen20 mgPEN-GLP2-20Not yet published

2 catalog listings are covered here. Sizes, SKUs and documentation status are read from the catalog at build time. Blends contain more than one molecule, so only single-component listings behave as a single-analyte standard. Pricing is per account: see wholesale pricing.

03

What a certificate of analysis must show

Four structural features, each separately checkable.

Because the structure is public, a tirzepatide certificate can be audited field by field. The two Aib residues, the C20 diacid side chain with its gamma-glutamate and glycol linker, and the C-terminal amide are each a distinct feature with a mass consequence. A peptide missing both Aib substitutions, or carrying a free-acid C-terminus instead of the amide, produces a different calculated mass.

Identity at 4813.5 g/mol comes from multiple charge states: roughly m/z 1204.4 for the quadruply charged ion and 963.7 for the quintuply charged. As with any acylated peptide, unacylated material is the related substance most worth quantifying, because it is both a likely manufacturing failure and several hundred daltons away. Marogen publishes released certificates by lot number at marogenbio.com/coa, with a lookup at marogenbio.com/lot. No tirzepatide lot has a published certificate today, so request one with the quote.

What a certificate of analysis must show
FieldWhat it has to say for tirzepatide
Material nameTirzepatide or LY3298176. GP-2 and GLP-2 are labels, and GLP-2 names a different hormone
Lot numberAs printed on the vial or pen, matching the label exactly
IdentityObserved against calculated mass across charge states: near m/z 1204.4 for [M+4H]4+ and 963.7 for [M+5H]5+, from 4813.5 g/mol
Aib positionsAlpha-aminoisobutyric acid at residues 2 and 13, not alanine or glycine substitutes
Side chainThe C20 diacid at Lys20 via a gamma-glutamate and two glycol units, with unacylated material quantified
C-terminusSerinamide, not the free acid. The acid is roughly 1 Da heavier
PurityArea percent by reverse-phase HPLC with gradient and wavelength stated
Salt formFree peptide, sodium salt or acetate, each a different weighing basis
ContentMilligrams actually present, reported separately from purity
04

Storage and handling in the lab

Tirzepatide behaves like the lipidated peptide it is. The fatty-diacid side chain makes the molecule surface-active, so adsorption onto glass and plastic and aggregation in solution are both real, and neither shows up as a change in purity. There is one tryptophan in the backbone, which adds a mild light sensitivity. Marogen does not publish per-material storage conditions, so confirm the condition for your lot with the wholesale team. The points below are general laboratory practice, not a Marogen specification.

  • Keep the solid sealed, dry and cold, and bring the vial to room temperature before opening so moisture does not condense into the powder.
  • Expect adsorption losses at low concentration, and keep transfers and handling steps to a minimum.
  • Avoid shaking and repeated freezing and thawing of made-up solutions, since aggregation is a physical change a purity figure does not report.
  • Keep solutions out of direct light, and record the lot number, salt form and mass basis together.
05

Telling it apart from related compounds

The useful separations here are from retatrutide, from semaglutide, and from the genuine hormone whose name the pen borrows. Retatrutide is the closest in mass at roughly 82 Da away, which is under two percent and needs a decent instrument reported across charge states. GLP-2 is not a mass problem at all; it is a naming problem, and the only fix is to use the word tirzepatide.

Telling it apart from related compounds
MaterialHow it differs and how to check
Retatrutide (GP-3)4731.3 g/mol against 4813.5, about 82 Da apart, and a different backbone. Marogen lists it separately as a standard and a pen
Semaglutide (GP-1)A smaller GLP-1 analogue near 4113 g/mol with a different side chain. Clearly separable by mass
GLP-2, the real hormoneA distinct natural 33-residue intestinal hormone. Tirzepatide is not GLP-2 and does not act at its receptor
Backbone without the side chainSeveral hundred daltons lighter and far more polar, so retention shifts clearly. A manufacturing failure, not a grade
06

What the published literature measured

The structural and in-vitro record for tirzepatide is solid and comes from two papers. Both are receptor-pharmacology work, which is the part that matters for a reference standard, because it is what the molecule's identity was defined against.

  1. Coskun T, Sloop KW, Loghin C, et al.. Molecular Metabolism 2018; 18:3-14.

    Reported the structure, including the two Aib substitutions and the C20 fatty-diacid side chain, and measured receptor binding and cAMP responses in vitro.

  2. Willard FS, Douros JD, Gabe MB, et al.. JCI Insight 2020; 5:e140532.

    Measured receptor binding, cAMP accumulation and beta-arrestin recruitment at the GIP and GLP-1 receptors, showing the imbalance between the two.

07

Wholesale availability

The tirzepatide vial in six sizes and the 20 mg pen are supplied wholesale, priced per account rather than from a public list. One pricing request can cover both formats, and the quote confirms availability, lead time, documentation status and, for the pen, the fill volume the site does not publish.

Apply for wholesale pricing

List the materials, sizes and units you need, or ask about the range, and say a little about the business. Pricing is set per account and confirmed on every quote, with the lot’s documentation status stated for each line.

08

Questions

Is tirzepatide the same as GLP-2?

No, and the names should not be mixed. GLP-2, glucagon-like peptide-2, is a distinct natural 33-residue intestinal hormone. Tirzepatide is a synthetic 39-residue lipidated analogue based on the GIP sequence, and it does not act at the GLP-2 receptor. Marogen's pen is listed under the name GLP-2 and its reference standard under GP-2, but both are supplier labels; tirzepatide is the only accurate name for the molecule.

What is tirzepatide as a molecule?

A synthetic 39-residue lipidated peptide amide based on human GIP, development code LY3298176, CAS 2023788-19-2, formula C225H348N48O68, 4813.5 g/mol. The documented modifications are Aib at positions 2 and 13, a C20 fatty diacid at Lys20 attached through a gamma-glutamate and two glycol units, and a C-terminal serinamide. These figures agree across PubChem and the FDA registry.

What formats does Marogen stock tirzepatide in?

Two: a lyophilized vial in six strengths from 5 mg to 60 mg, and a 20 mg prefilled research pen listed as GLP-2. There is no nasal spray. The pen's concentration and fill volume are not published, only its total content.

What should a tirzepatide certificate of analysis show?

Because the structure is public, the certificate can be audited feature by feature: the molecule named as tirzepatide, the lot number, laboratory and date, identity across several charge states, the two Aib positions, the C20 side chain with unacylated material quantified, the C-terminal amide rather than the free acid, purity with the method stated, and content separate from purity.

How do I separate tirzepatide from retatrutide on a certificate?

By mass, carefully. They sit about 82 Da apart, 4813.5 against 4731.3, which is under two percent of the total and not something a low-resolution reading will settle. A certificate should report the observed against calculated mass across at least two charge states, which makes the difference unambiguous. The backbones also differ, so a sequence statement plus a properly reported mass together is what you want to see.

Research use only. This guide describes materials supplied for in-vitro research and analytical method development. Nothing here is dosing, administration or use information, and no product on this site is offered for human or animal consumption. See the research use policy.